Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review.

Internal medicine (Tokyo, Japan) - 1 Apr 2021

Yoshimatsu Yuki, Ebi Noriyuki, Ooi Ryunosuke, Sueyasu Takuto, Nishizawa Saori, Munechika Miyuki, Yoshimine Kohei, Ko Yuki, Ide Hiromi, Tsuruno Kosuke, Tobino Kazunori

Abstract excerpt

The efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung squamous cell carcinoma is said to be low. Thus far, only four cases of osimertinib in lung squamous cell carcinoma have been published. We experienced a case of EGFR mutant lung squamous cell carcinoma in which fifth-line treatment with osimertinib was effective after T790M EGFR mutation turned positive. Osimertinib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Carcinoma, Squamous Cell

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 33132329
DOI: 10.2169/internalmedicine.5463-20
PMCID: PMC8079920

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review.PMID 33132329Read ↗

Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M-positive: Case report and literature review.Semantic proximity Read ↗

Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation-Case Report and a Literature Review.Semantic proximity Read ↗

First-Line Osimertinib for EGFR-Mutated Squamous Cell Lung Carcinoma: A Case Report.Semantic proximity Read ↗

Next-generation sequencing clarified why first-line treatment with osimertinib was ineffective in an autopsied case of EGFR-mutated lung squamous cell carcinoma.Semantic proximity Read ↗

First-line osimertinib treatment in patients with lung squamous cell carcinoma harboring active epidermal growth factor receptor mutations.Semantic proximity Read ↗

Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation.Semantic proximity Read ↗

Successful administration of low-dose almonertinib in a patient with lung adenocarcinoma after osimertinib-induced interstitial lung disease: a case report and literature review.Semantic proximity Read ↗

Salvage Chemotherapy Following Osimertinib in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.Semantic proximity Read ↗

Transformations First Into Squamous-Cell Carcinoma and Later Into Sarcomatoid Carcinoma After Acquired Resistance to Osimertinib in a Patient With EGFR-Mutant Lung Adenocarcinoma: Case Report.Semantic proximity Read ↗

T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.Semantic proximity Read ↗

Osimertinib for the Treatment of EGFR Mutation-Positive Lung Adenocarcinoma Complicated With Dermatomyositis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.